Prime Capital Investment Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Prime Capital Investment Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-24,550	Closed	-$2.5M	–	813
2023 Q2	$2.5M	Buy	24,550 +18,850	+331%	+$1.78M	0.05%	234
2023 Q1	$518K	Buy	+5,700	New	+$334K	0.02%	338

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prime Capital Investment Advisors's RETA Position: Q3 2023 in Review

Prime Capital Investment Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 24,550 shares — an estimated $2.5M sold.

Prime Capital Investment Advisors first reported a position in RETA in Q1 2023 and held it in 2 quarters. The position peaked at $2.5M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Prime Capital Investment Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Prime Capital Investment Advisors sold 24,550 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.5M.
Prime Capital Investment Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 2 quarters.
Prime Capital Investment Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.5M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Prime Capital Investment Advisors's 13F filing for Q3 2023, filed 9 Nov 2023.